Covered recipient · General Payments record
ANDREW MICHAEL LERMAN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Epilepsy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$28,694.51
237 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,507.08 | 11 |
| Food and Beverage | $5,314.13 | 221 |
| Consulting Fee | $4,000.00 | 1 |
| Travel and Lodging | $873.30 | 4 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Neurocrine BioSciences, Inc. | $11,387.81 | 37 |
| Neurelis, Inc. | $6,199.11 | 13 |
| Amneal Pharmaceuticals LLC | $4,997.03 | 9 |
| ABBVIE INC. | $2,589.64 | 21 |
| UCB, Inc. | $479.76 | 12 |
| Abbott Laboratories | $400.22 | 8 |
| UPSHER-SMITH LABORATORIES LLC | $355.40 | 25 |
| Biohaven Pharmaceutical Holding Company Ltd. | $323.51 | 19 |
| JAZZ PHARMACEUTICALS INC. | $248.82 | 12 |
| SK Life Science, Inc. | $241.53 | 11 |
| Allergan, Inc. | $207.53 | 8 |
| Lundbeck LLC | $175.94 | 6 |
| Teva Pharmaceuticals USA, Inc. | $156.00 | 9 |
| Avion Pharmaceuticals | $135.78 | 9 |
| IMPEL PHARMACEUTICALS INC. | $134.12 | 7 |
| Amgen Inc. | $98.20 | 4 |
| Kyowa Kirin, Inc. | $76.65 | 4 |
| ARGENX US, INC. | $74.78 | 3 |
| GENZYME CORPORATION | $65.18 | 3 |
| GRT US Holding, Inc. | $64.54 | 3 |
| Supernus Pharmaceuticals, Inc. | $51.57 | 3 |
| Novartis Pharmaceuticals Corporation | $48.53 | 2 |
| Sunovion Pharmaceuticals Inc. | $46.05 | 2 |
| Lilly USA, LLC | $43.02 | 2 |
| Biogen, Inc. | $37.67 | 2 |
| Alfasigma USA, Inc. | $23.00 | 1 |
| Medtronic, Inc. | $20.42 | 1 |
| ACADIA Pharmaceuticals Inc | $12.70 | 1 |
Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANDREW MICHAEL LERMAN
NPI 1407173974 · CMS profile ID 1326930
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Epilepsy
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1407173974?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANDREW MICHAEL LERMAN, NPI 1407173974, CMS profile ID 1326930. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407173974?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). ANDREW MICHAEL LERMAN, NPI 1407173974, CMS profile ID 1326930. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407173974?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- ANDREW MICHAEL LERMAN, NPI 1407173974, CMS profile ID 1326930, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1407173974?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
237 matching records · $28,694.51 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 237.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $5.04 | 10/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893186957 | CMS |
| Abbott Laboratories | $23.28 | 10/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 910325729 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $14.81 | 10/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 912317667 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $0.60 | 10/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 912317671 | CMS |
| ABBVIE INC. | $19.89 | 09/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893186955 | CMS |
| Avion Pharmaceuticals | $24.15 | 09/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 926512741 | CMS |
| Lundbeck LLC | $25.54 | 09/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945772253 | CMS |
| IMPEL PHARMACEUTICALS INC. | $23.99 | 09/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 962306167 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.01 | 09/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923651989 | CMS |
| JAZZ PHARMACEUTICALS INC. | $4.36 | 09/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951387269 | CMS |
| ABBVIE INC. | $18.15 | 09/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893186953 | CMS |
| Neurocrine BioSciences, Inc. | $2,800.00 | 09/22/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963318031 | CMS |
| Neurocrine Biosciences, Inc. | $96.00 | 09/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963318035 | CMS |
| Neurocrine Biosciences, Inc. | $23.09 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317937 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $7.15 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 912317663 | CMS |
| Amgen Inc. | $22.37 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939356811 | CMS |
| JAZZ PHARMACEUTICALS INC. | $23.87 | 09/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951387247 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $9.67 | 09/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923651987 | CMS |
| Lundbeck LLC | $34.63 | 09/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945772249 | CMS |
| Neurelis, Inc. | $1,202.00 | 09/13/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950153581 | CMS |
| Neurocrine Biosciences, Inc. | $4,000.00 | 09/13/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317953 | CMS |
| Amgen Inc. | $32.05 | 09/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939356809 | CMS |
| ABBVIE INC. | $8.99 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893186951 | CMS |
| ARGENX US, INC. | $17.79 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951638587 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $0.94 | 08/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923651983 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.59 | 08/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923651985 | CMS |
| GRT US Holding, Inc. | $13.88 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894636211 | CMS |
| Neurocrine Biosciences, Inc. | $20.57 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317935 | CMS |
| JAZZ PHARMACEUTICALS INC. | $15.36 | 08/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951387137 | CMS |
| Lundbeck LLC | $31.99 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945772245 | CMS |
| Neurelis, Inc. | $1,780.00 | 08/18/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950153579 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.61 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923651981 | CMS |
| Neurelis, Inc. | $1,113.00 | 08/17/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950153577 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $7.27 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 912303089 | CMS |
| UCB, Inc. | $24.25 | 08/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908061783 | CMS |
| Amgen Inc. | $21.57 | 08/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939356807 | CMS |
| Teva Pharmaceuticals USA, Inc. | $25.34 | 08/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954425813 | CMS |
| Neurocrine Biosciences, Inc. | $6.89 | 08/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317925 | CMS |
| Neurocrine Biosciences, Inc. | $1.58 | 08/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317929 | CMS |
| Neurocrine Biosciences, Inc. | $5.35 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317931 | CMS |
| Sunovion Pharmaceuticals Inc. | $22.94 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920965663 | CMS |
| GRT US Holding, Inc. | $29.27 | 08/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894636207 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.56 | 08/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923651979 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $16.28 | 08/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 912311923 | CMS |
| Amneal Pharmaceuticals LLC | $22.78 | 08/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956585191 | CMS |
| Neurocrine Biosciences, Inc. | $2.81 | 07/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317919 | CMS |
| Neurocrine Biosciences, Inc. | $21.77 | 07/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963317923 | CMS |
| IMPEL PHARMACEUTICALS INC. | $21.67 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 962306165 | CMS |
| Neurelis, Inc. | $98.13 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950153575 | CMS |
| Supernus Pharmaceuticals, Inc. | $17.15 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 952992665 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,197,791.18 | 29 |
| PY2024 | Recipient | $110,925.00 | 2 |
| PY2024 | Principal investigator | $1,637,807.41 | 14 |
| PY2023 | Recipient | $4,889.58 | 1 |
| PY2023 | Principal investigator | $900,023.23 | 16 |
| PY2022 | Recipient | $24,024.00 | 2 |
| PY2022 | Principal investigator | $433,543.60 | 9 |
| PY2021 | Recipient | $169.80 | 1 |
| PY2021 | Principal investigator | $8,992.21 | 2 |
| PY2020 | Recipient | $7,997.00 | 1 |
| PY2020 | Principal investigator | $35,926.17 | 3 |
| PY2019 | Recipient | $7,910.00 | 1 |
| PY2019 | Principal investigator | $1,918.59 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
29 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,731.00 | 12/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223289754 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,731.00 | 12/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223289756 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,731.00 | 12/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223289758 |
| Principal investigator 1 | Genentech, Inc. | $3,850.00 | 12/11/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | Alzheimer's Disease Master Pre Screener | No dispute reported | 06/30/2026 | 1211682520 |
| Principal investigator 1 | Genentech, Inc. | $9,380.00 | 11/20/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | Alzheimer's Disease Master Pre Screener | No dispute reported | 06/30/2026 | 1211682518 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,960.75 | 11/20/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223288639 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,731.00 | 10/16/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223287047 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $252.10 | 10/13/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223286719 |
| Principal investigator 1 | ARGENX US, INC. | $63,893.20 | 10/10/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161469 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $281,035.88 | 10/08/2025 | Non-covered Recipient Entity GABLES NEUROLOGY | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190308798 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 09/18/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | Alzheimer's Disease Master Pre Screener | No dispute reported | 06/30/2026 | 1211682516 |
| Principal investigator 1 | ARGENX US, INC. | $10,625.00 | 09/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1237161457 |
| Principal investigator 1 | ARGENX US, INC. | $2,600.00 | 09/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1237161462 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,664.75 | 09/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223285478 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,317.00 | 09/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223285480 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,362.01 | 09/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223285482 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,731.00 | 09/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223285492 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,731.00 | 09/17/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223285520 |
| Principal investigator 1 | Eli Lilly and Company | $17,860.00 | 08/04/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY | No dispute reported | 06/30/2026 | 1187892932 |
| Principal investigator 1 | Eli Lilly and Company | $15,495.00 | 03/11/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187891414 |
| Principal investigator 1 | ARGENX US, INC. | $15,000.00 | 03/05/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161465 |
| Principal investigator 1 | Eli Lilly and Company | $290,748.00 | 02/25/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187892922 |
| Principal investigator 1 | Eli Lilly and Company | $17,866.00 | 02/18/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187892678 |
| Principal investigator 1 | Eli Lilly and Company | $348,473.00 | 02/10/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187892734 |
| Principal investigator 1 | Eli Lilly and Company | $6,130.59 | 01/27/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187892738 |
| Principal investigator 1 | Eli Lilly and Company | $9,918.93 | 01/09/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187893446 |
| Principal investigator 1 | Eli Lilly and Company | $869.23 | 01/09/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187893450 |
| Principal investigator 1 | UCB SA | $59,814.00 | 01/07/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246657990 |
| Principal investigator 1 | Eli Lilly and Company | $6,289.74 | 01/02/2025 | Non-covered Recipient Entity VISIONARY INVESTIGATORS NETWORK | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187892670 |